Subscribe

Study Summaries

GOG 241: Phase III Randomized Trial in Patients with Mucinous Epithelial Ovarian Cancer

Neither oxaliplatin-capecitabine nor bevacizumab significantly improved OS or PFS compared to paclitaxel-carboplatin in advanced-stage mucinous ovarian cancer.

GOG 205: Radiation for Locally Advanced Vulvar Cancer

The combination of radiation therapy with weekly cisplatin chemotherapy is effective in achieving high complete clinical and pathological response rates with manageable toxicity for the treatment of locally-advanced vulvar carcinoma.

Prospective Phase II Trial of Levonorgestrel Intrauterine Device

GOG 173: Sentinel LND in Vulvar Cancer

MILO/ENGOT-ov11: Binimetinib in Recurrent Low-Grade Serous

In low-grade serous ovarian cancer, Binimetinib did not significantly improve PFS compared to standard of care chemotherapy.

SOC-1

Surgery did not improve overall survival, but it showed a benefit in certain analyses. This supports the potential efficacy of secondary cytoreduction in specialized centers and for selected patients.

AURELIA Trial: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer

Adding bevacizumab to chemotherapy significantly improves PFS and ORR in patients with platinum-resistant recurrent ovarian cancer.

OCEANS Trial: Bevacizumab Maintenance in Platinum Sensitive Recurrence

- Adding bevacizumab to gemcitabine and carboplatin significantly improves PFS but no difference in OS in platinum-sensitive recurrence

MITO 16B/MANGO-OV2/ENGOT-OV17: Bev Maintenance with Platinum Doublets in Platinum-sensitive Recurrence

Continuing bevacizumab beyond progression combined with chemotherapy significantly improves progression-free survival in patients with platinum-sensitive recurrent ovarian cancer compared to standard chemotherapy alone, but no OS benefit

GOG 213: Maintenance Bevacizumab in Platinum Sensitive Recurrence

The addition of bevacizumab to standard chemotherapy (paclitaxel and carboplatin) improves PFS significantly and may offer a clinically meaningful improvement in OS.